Effectiveness and cost of bisphosphonate therapy in tumor bone disease

Cancer

Volumn 97, Issue 3 SUPPL., 2003, Pages 859-865

  Body, Jean Jacques ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Bisphosphonate; Bone metastases; Breast carcinoma; Cost effectiveness; Myeloma; Pain; Quality of life; Radiotherapy; Tumor bone disease

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

BONE METASTASIS; BONE PAIN; BREAST CARCINOMA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; MYELOMA; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; VERTEBRA FRACTURE;

EID: 0037301971     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11139     Document Type: Conference Paper

References (30)

1. Body JJ. Bone metastases. In: Klastersky J, Schimpff SC, Senn HJ, editors. Handbook of supportive care in cancer. 2nd edition. New York: Marcel Dekker, Inc., 1999:453-481.
2. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61-66.
3. Body JJ, editor. Tumor bone diseases and osteoporosis in cancer patients. New York: Marcel Dekker, Inc., 2000.
4. Kanis JA, McCloskey EV. Bisphosphonates in the treatment of multiple myeloma. In: Body JJ, editor. Tumor bone diseases and osteoporosis in cancer patients. New York: Marcel Dekker, Inc., 2000:457-481.
5. McCloskey EV, Guest JF, Kanis JA. The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs. 2001;61:1253-1274.
6. Mundy GR. Mechanisms of bone metastasis. Cancer. 1997; 80:1546-1556.
7. Body JJ. Bisphosphonates as chemotherapeutic agents. Curr Opin Oncol Endocr Metab Invest Drugs 2000;2:155-161.
8. Body JJ, Bartl R, Burckhardt P, et al., for the International Bone and Cancer Study Group. Current use of bisphosphonates in oncology. J Clin Oncol. 1998;16:3890-3899.
9. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11:59-65.
10. Hortobagyi GN, Theriault RL, Lipton A, et al. for the Protocol 19 Aredia Breast Cancer Study Group. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol. 1998;16:2038-2044.
11. Theriault RL, Lipton A, Hortobagyi GN, et al., for the Protocol 18 Aredia Breast Cancer Study Group. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol. 1999;17:846-854.
12. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88:1082-1109.
13. McCloskey EV, MacLennan ICM, Drayson M, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Hematol. 1998;100:317-325.
14. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I, for the Finnish Leukaemia Group. Randomized placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet. 1992;340:1049-1052.
15. Berenson JR, Lichtenstein A, Porter L, Dimopoulous A, Bordoni R, George S, et al. for the Myeloma Aredia Study Group. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol. 1998;16:593-602.
16. Body JJ, Lichinitser MR, Diehl I, et al. Double-blind placebo-controlled trial of intravenous ibandronate in breast cancer metastatic to bone [abstract 2222]. Proc Am Soc Clin Oncol. 1999;18:575a.
17. Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res. 1999; 14:1557-1561.
18. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19:558-567.
19. Rosen LS, Gordon D, Antonio BS, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377-387.
20. Lipton A, Demers L, Curley E, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer. 1998;34:2021-2026.
21. Major PP, Lipton A, Berenson J, Hortobagyi G. Oral bisphosphonates: a review of clinical use in patients with bone metastases. Cancer. 2000;88:6-14.
22. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol. 2000;18:1378-1391.
23. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15:613-620.
24. Laakso M, Lahtinen R, Virkkunen P, Elomaa I. Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Br J Haematol. 1994;87:725-729.
25. Bruce NJ, McCloskey EV, Kanis JA, Guest JF. Economic impact of using clodronate in the management of patients with multiple myeloma. Br J Haematol. 1999;104:358-364.
26. Dranitsaris G, Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer. 1999;7:271-279.
27. Hillner BE, Weeks JC, Desch CE, Smith TJ. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000;18:72-79.
28. Beusterien KM, Hill MC, Ackerman SJ, Zacker C. The impact of pamidronate on inpatient and outpatient services among metastatic breast cancer patients. Support Care Cancer. 2001;9:169-176.
29. DesHarnais Castel L, Bajwa K, Markle JP, Timbie JW, Zacker C, Schulman KA. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer. 2001;9:545-551.
30. Kanis JA, MacCloskey EV, Powles T, Paterson AH, Ashley S, Spector T. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer. 1999;79:1179-1181.